Meet our leadership team

pink dots icon

Decades of experience, dozens of perspectives

We value diversity of background and mindset just as highly as experience and technical knowledge.

Our executive team, board, and scientific personnel are a diverse mix of ages, genders, backgrounds, and ethnicities, with more than 80% holding PhDs with specialties from cell biology to computer science.

It’s this diversity and originality, powered by a shared passion for delivering innovative healthcare solutions for all, that truly makes the SOPHiA GENETICS team unique.

Our Executive Team

Jurgi Camblong

Founder and CEO

Dr. Jurgi Camblong is a visionary entrepreneur who is pioneering the data-driven medicine movement around the world.

He is a molecular biologist (published in Cell, Science and Nature), has a PhD in life sciences from the University of Geneva and an EMBA in management of technology from EPFL/HEC Lausanne.

In 2011, he founded SOPHiA GENETICS with Dr. Pierre Hutter and Prof. Lars Steinmetz. He has since successfully led the development of the company, listed among the 50 Smartest Companies by the MIT Technology Review. Jurgi has been a member of the Advisory Council on Digital Transformation to the Swiss government and was personally recognized by EY as Emergent Entrepreneur of the Year in 2017.

Lara Hashimoto

SVP – Chief Business Officer

Lara Hashimoto joined SOPHiA GENETICS in 2020.

She started in the industry 20 years ago as a scientist at Roche Pharma based in Basel, Switzerland. She held several positions spanning pharma clinical drug development, business analytics and strategic marketing in the global organization as well as sales and operational marketing positions in the Canadian affiliate.

In 2009, Lara moved to Roche Molecular Diagnostics in California as the lifecycle leader responsible for the genomics and oncology IVD product portfolio and pipeline, launching several companion diagnostics globally. Lara then became the general manager of Roche Diagnostics New Zealand Ltd where she grew sales above market for 4 consecutive years.

Returning to the Bay Area, Lara then joined the newly formed Roche Sequencing Solutions team where she was the vice president responsible for non-invasive prenatal testing and the Nanopore Sequencer before being appointed chief commercial officer.

Growing up in Canada, Lara developed an early interest in understanding the role of genetics in common diseases. This took her from studying the genetics of multiple sclerosis at the University of Western Ontario to joining the Wellcome Trust Centre for Human Genetics at the University of Oxford, UK.

Philippe Menu

SVP – Chief Medical Officer

Dr. Philippe Menu, MD, PhD, MBA, brings a unique blend of medical expertise across clinical medicine, fundamental research in molecular biology and business management consulting. He joined SOPHiA GENETICS in 2020 from McKinsey & Company, where he had spent the last 8 years serving dozens of clients in the BioPharma sector, advising global pharmaceutical companies, mid-size players and biotechs alike across the pharma value chain with a major focus on innovative therapies and diagnostics in oncology and rare diseases.

Philippe obtained his MD and PhD from the University of Lausanne, and his MBA in life sciences from the Open University Business School.

Ross Muken

SVP – Chief Financial Officer

Ross Muken joined SOPHiA GENETICS in February 2021. He was most recently the CFO and COO of Click Therapeutics.

Before joining Click, he was partner, senior managing director and head of the healthcare services & technology research team at Evercore ISI where he covered more than 50 companies across the healthcare technology & distribution, life science Tools & diagnostics, managed care & facilities and medical supplies & devices subsectors.

Prior to joining Evercore ISI, Ross served as a managing director at Deutsche Bank Securities and spent time in the equity research division of Thomas Weisel Partners. He began his career as an M&A investment banker at Bank of America Securities after earning his BS in business administration, magna cum laude, at Boston University.

Manuela Valente

SVP – Chief People Officer

Manuela Da Silva Valente is a seasoned human resources executive with more than 20 years’ experience working in international companies.

Manuela joined SOPHiA GENETICS in January 2019 from IQVIA (formerly Quintiles and IMS Health Inc.), a human data science company, where she held a number of senior human resources roles, including global senior human resources director.

Prior to this, she worked for several years at Outcome Sciences, where she successfully established the European operations and led the organization through an acquisition by Quintiles, a global clinical research organization.

Manuela obtained a bachelor’s degree in business administration from the Business Management School of Zurich and a management & human resources diploma from CEFCO Lausanne.

Used to work in fast-pacing companies, Manuela has extensive experience in aligning people strategies with business objectives and driving significant organizational and cultural changes by focusing on talent development and employee engagement.

Daan Van Well

SVP – Chief Legal Officer and General Counsel

Daan van Well, LL.M, MBA, has more than 20 years of experience as a lawyer in top-tier private practice, in-house and consulting roles. He has extensive experience in legal, governance and compliance matters.

Prior to joining SOPHiA GENETICS in June 2019, he was the head of legal at PwC in Geneva, Switzerland where he supported a variety of healthcare and other clients with company mergers and acquisitions, business development, governance and compliance matters.

Before that, after having held several in-house roles, Daan served as corporate secretary for international food retailer Ahold (currently Ahold-Delhaize), listed at the New York Stock Exchange and at AEX Euronext Amsterdam, where he oversaw all corporate activities, corporate finance and investor relations work.

He started his career as a lawyer at international law firm Loyens & Loeff in Rotterdam, The Netherlands. Daan holds an LL.M in Dutch civil law from Utrecht University and an executive MBA in management and corporate finance from HEC Lausanne.

In parallel to his legal career, Daan has co-founded low/no-alcohol craft beer company ABLOC. Daan is an avid cycling enthusiast and loves to go the extra mile.

Zhenyu Xu

SVP – Chief Scientific Officer

Dr. Zhenyu Xu is a genome scientist with a background in molecular and computational biology. Zhenyu is among the most experienced bioinformaticians in clinical NGS data analysis worldwide. He joined SOPHiA GENETICS in 2012 and is the leader of the technology team that developed the SOPHiA DDM™ platform — the universal technology for data-driven medicine.

Zhenyu holds a master’s degree from Cambridge University in computational biology and obtained his PhD at the European Molecular Biology Laboratory, where he focused on the transcriptome landscape of yeast. His PhD work systematically characterized the non-coding transcripts in yeast that lead to the unveiling that, in a majority of cases, transcriptions are bidirectional.

Melissa Finocchio

SVP – Chief Regulatory Officer

Melissa Finocchio is an experienced regulatory and quality professional with more than 20 years of experience in in vitro diagnostics. Before joining SOPHiA Genetics in May 2021, she worked for bioMérieux where she held various positions in product development, project management, complaint handling, labeling, and quality. Having lived and worked in multiple countries, she has experienced first-hand the challenges of cross-cultural communication and international management on a global scale and is passionate about the role of quality in facilitating efficient operations. She received her undergraduate degree in Engineering Management from the University of Missouri-Rolla (now Missouri University of Science & Technology) and her Master’s degree in Quality Management from Webster University. She is also an American Society of Quality certified Reliability Engineer and Quality Engineer.

Abhimanyu (Abhi) Verma

SVP – Chief Technology Officer

Abhimanyu (Abhi) Verma is a healthcare technology leader experienced in developing capabilities and leading multifunctional organizations to create and accelerate patient impacting solutions. He has 17+ years of life sciences industry experience centered on harnessing the intersection of people, science, technology, data & AI serving multiple therapeutic areas and functions across the pharma value chain.

His leadership experience spans creating technology & information strategies; operating models; building teams and products; running operational platforms, driving organizational and cultural transformation with a relentless focus on outcomes and execution. Previously at Novartis, Abhi has proven to be a thought leader and execution champion at innovating and scaling data science and technology products, methodologies and approaches. He brings diverse insights and leadership experience from working across different locations and functions, such as creating the technology and data foundations on Real World Evidence and establishing digital-driven capabilities and standards in Drug Development. Most recently, he incubated and scaled several technology platforms and products along with the architecture of the foundational technical infrastructure. These products, platforms and technologies underpin the digital transformation at Novartis.

Passionate about cycling, comics, science fiction and history, Abhi holds a MBA from the Indian School of Business, a Masters in Science in Pharmaceutical Medicine and is an Engineer. He is also co-founder of the nonprofit Health Hacking Lab.

Peter Casasanto

SVP – Chief BioPharma Officer

Peter Casasanto is an executive in the life sciences industry with experience and expertise spanning both corporate and business development and sales strategy, supporting biomarker development and precision medicine. He started in the industry 15 years ago as a scientist at Merck in their Vaccines & Biologics group. After completing his M.B.A., Peter moved into leading the business development efforts for PPD and their Vaccines division, after they successfully acquired the Merck research and testing lab as part of a strategic divestiture and partnership between the Pharma and CRO.

In 2013, Peter began working at LabCorp in their Clinical Trials division as a Director of business development, supporting the sales, client management and growth strategy of the BioPharma portfolio. In 2016 he became Executive Director and Head of Corporate Development for the Pharma Services division of NeoGenomics, managing the inorganic growth of the company through M&A and strategic B2B partnerships. In 2019, Peter joined Tempus Labs where he was the Vice President responsible for the Life Sciences division, working with BioPharma partners across Real World Data/Evidence, Data Science, Clinical Trial Matching and genomic Sequencing as a Service, including CDx programs.

Most recently, Peter has worked at CellCarta as the Vice President of New Commercialization Initiatives, leading the commercial strategies for new corporate initiatives spanning companion diagnostics/single-site IVD, new product launch and Go-to-Market for an in-house developed SaaS (software) analytics platform, as well as AI-driven mutiomic-based insights and predictions. He also sat on the M&A Deal Team for new technology evaluation, licensing, due diligence and strategic B2B partnerships.

Peter holds a M.B.A in Pharmaceutical Management from Drexel’s LeBow College of Business, a Master’s degree in Biomedical Chemistry from Thomas Jefferson Medical School and Bachelor of Science in Immunology & Genomics from the University of Maryland at College Park.

Ken Freedman

SVP – Chief Revenue Officer

Ken Freedman joined SOPHiA GENETICS in 2022. He is an accomplished executive with more than 25 years of sales, marketing, and executive management experience. His background includes sales, management, and holding executive roles for some of the most innovative providers of technology to the world-wide media space including Agfa, FileFlow, Prepress Solutions, and MediaSpan.

Ken was part of the executive team involved in selling MediaSpan to Vista Equity Partners during the early days of Newscycle. An expert at finding and growing new revenue streams, building processes, and helping customers find success, he ultimately went on to lead all sales activities from Canada to Latin America.

Ken graduated from UMass Amherst with a degree in Mass Communications. He lives in Falmouth, MA with his wife and has two daughters.

Board of Directors

Jurgi Camblong

Founder and CEO

Dr. Jurgi Camblong is a visionary entrepreneur who is pioneering the data-driven medicine movement around the world.

He is a molecular biologist (published in Cell, Science and Nature), has a PhD in life sciences from the University of Geneva and an EMBA in management of technology from EPFL/HEC Lausanne.

In 2011, he founded SOPHiA GENETICS with Dr. Pierre Hutter and Prof. Lars Steinmetz. He has since successfully led the development of the company, listed among the 50 Smartest Companies by the MIT Technology Review. Jurgi has been a member of the Advisory Council on Digital Transformation to the Swiss government and was personally recognized by EY as Emergent Entrepreneur of the Year in 2017.

Troy Cox

Chairman of the Board

Troy Cox is a pioneer in the precision medicine revolution. Former CEO of Foundation Medicine (acquired by Roche in 2018), Troy is making a difference in patient’s lives by serving on corporate boards of innovative companies in the BioPharma, diagnostics and tech industries.

He is also committing his support to patient-focused non-profit organizations. In June 2019, Troy joined SOPHiA GENETICS’ Board of Directors to help the organization further advance data-driven medicine.

Prior to Foundation Medicine, Troy served as senior vice president and officer at Genentech where he led US bio-oncology for a period of unprecedented growth, participating in the launch of nearly half of the products from the world’s oncology leader. Other notable experiences include UCB, Sanofi-Aventis and Schering-Plough.

Troy’s expertise spans across strategy, general management, commercial and R&D. His pharmaceutical career began as a sales representative after earning his MBA at the University of Missouri. He also received a BBA in finance from the University of Kentucky.

Kathy Hibbs

Board Member

Kathy Hibbs is an accomplished healthcare technology executive and active board member with more than two decades of expertise in healthcare and genomics. She is the chief administratory officer of 23andMe, where she leads its complex legal operations and regulatory affairs. She is globally recognized for her effectiveness, having successfully pioneered the first FDA clearance for over-the-counter genetic testing.

Regularly recognized as one of the Bay Area’s most influential women by the both the San Francisco Business Times and Silicon Valley Business Journal, Kathy is ranked by Chambers as among the most influential general counsels in US. She sits on the boards of Decipher Biosciences, Inc. and Cadex Genomics Inc. During her 15 years as an executive officer and corporate secretary for two public biotechnology companies, Genomic Health, Inc. (NASDAQ: GHDX) and Monogram Biosciences, Inc. (NASDAQ: MGRM), Kathy developed her passion for personalized medicine and the power of innovation to improve the lives of patients.

Kathy graduated summa cum laude from the University of California, Riverside and received her juris doctorate from Hastings College of the Law.

Didier Hirsch

Board Member

Didier Hirsch was senior vice president and chief financial officer of Agilent Technologies, Inc., a global leader in life sciences, diagnostics and applied chemical markets, from 2010 to 2018. He joined Agilent in 1999 at its inception, holding multiple leadership roles in finance.

Prior to joining Agilent, Didier was with Hewlett-Packard Company, serving in leadership roles in finance and administration in EMEA and Asia Pacific beginning in 1989. Previously, he held finance positions at Valeo Inc., Gemplus S.C.A., SGS-Thomson Microelectronics, I.B.H. Holding S.A., Bendix Corporation and Ford Motor Company.

Didier serves on the board of directors of Knowles Corporation. He is the chair of the audit committe and a memberof its nominating committee.

Didier holds a master’s degree in computer science from Toulouse University in France and a master’s degree in industrial administration from Purdue University in the US.

Vincent Ossipow

Board Member

Dr. Vincent Ossipow, CFA, is partner at Omega Funds and brings 22 years of healthcare investment experience in public and private companies.

Previously, Vincent worked with Sectoral Asset Management, a healthcare institutional investor, as a partner for private equity. Prior to that, he was with Pictet Bank where he co-managed the Pictet Biotech Fund.

Vincent has extensive board member experience. He has served on the board of directors of a dozen public and private companies over the past decade, including LifeSpan, Bioinvent (STO: BINV) and Immunic (NASDAQ: IMUX).

As a research fellow at the University of Geneva from 2000 to 2006, where he obtained a PhD in molecular biology, he worked on the molecular basis of brain function.

Vincent trained as a postdoctoral fellow (Hoffman-La-Roche and Human Frontier Science Program fellow) in Geneva and at the National Cancer Institute in Bethesda, Maryland. He completed a certificate in international finance and global markets at the Georgetown University School of Business in Washington, D.C.

Milton Silva-Craig

Board Member

Milton G. Silva-Craig is a successful leader who has demonstrated expertise in building inclusive, high performance teams that have grown and scaled businesses in various fields of provider healthcare IT, including medical imaging, revenue cycle management and clinical data management.

He has been the chief executive officer of Q-Centrix the past six years, leading the company through a successful sale from private equity firm Sterling Partners to TPG Growth in late 2018.

Prior to Q-Centrix, he served as president of TransUnion’s healthcare business unit, where, he developed and executed a strategic business plan focused on repositioning and growing TransUnion in the healthcare marketplace.

Prior to TransUnion, Milton served as the president and chief operating officer at Emageon Inc., leading the company’s strategic direction and operations. He grew revenues from several hundred thousand dollars to more than $100 million and eventually led Emageon through its initial public offering on NASDAQ in 2005 (NASDAQ:EMAG). He also held executive positions at General Electric Medical Systems.

Silva-Craig earned a JD from the University of Wisconsin School of Law in Madison and obtained his MBA and BA from the University of Wisconsin – Madison.

Tomer Berkovitz

Board Member

Dr. Tomer Berkovitz is a General Partner at aMoon, where he co-leads aMoon’s Growth Fund. As a former investment banker and senior executive in public companies, Tomer witnessed how the sectors of healthcare and technology were converging into a new industry that had the potential to make a global impact.

Tomer places his relationship with our portfolio companies’ CEOs and founders as his top priority, partnering with entrepreneurs to enhance the value and growth of their company. Since joining aMoon in early 2018, Tomer has led the $55M Series D round of Seer (NASDAQ: SEER) and supported the company through additional private financing, spin-off and successful IPO. Tomer also led the $55M Series B of PrognomIQ and the $30M Series C round of Zebra Medical Vision, serving as a board member in both companies. Tomer also led SOPHiA GENETICS’ $110M Series F round and serves as the Chairman of its Strategy Committee.

Tomer started his Wall Street career as an investment banker at J.P. Morgan in New York, where he was promoted to executive director in record time. In this role, he led numerous capital market and mergers and acquisitions transactions. After J.P. Morgan, Tomer was appointed CFO & COO of Alcobra, a NASDAQ listed biopharmaceutical company, where he led public equity offerings and its merger with Arcturus Therapeutics. Tomer earned his PhD in finance (with distinction) from Columbia Business School.

Jean-Michel Cosséry

Board Member

Jean-Michel is a senior healthcare executive with global leadership experience in research, marketing, and commercial roles in med-tech and pharmaceuticals. He worked in Novartis and Serono before joining GE Healthcare as the Chief Marketing Officer and Vice President Global Marketing. More recently, Jean-Michel was Vice President, North American Oncology at Eli Lilly, as well as Managing Director, Northern Europe.

He is currently a Board Director of Malin, a publicly listed investment company headquartered in Ireland, Exact Therapeutics, a publicly listed Norwegian biotech company, Diurnal Plc, a publicly listed specialty pharma company in London, UK, and Eracal Therapeutics, an early-stage privately owned biotech company based in Zurich, Switzerland.

Jean-Michel was previously a board member of the ABPI, as well as Chairman of the Board of the American Pharmaceutical Group. Jean-Michel was on the board of Immunocore until its IPO and Kymab until its sale to Sanofi.

Jean-Michel holds an MBA from the Rotterdam School of Management and a PhD with honors in Nuclear Chemistry and Neurobiology from the University of Paris. Additionally, he holds a PharmD with honors in Pharmacology from the University of Paris.

pink dots icon

Want to know more?
Get in touch with us.

Our client services team is on hand to help.